J Anesth Perioper Med. 2017;4(3):123-128. https://doi.org/10.24015/ebcmed.japm.2017.0027
From 1Department of Anesthesiology, West China Second University Hospital, Sichuan University, Chengdu, China; 2Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Correspondence to Dr. Xue-Mei Lin at email@example.com.
EBCMED ID: ebcmed.japm.2017.0027 DOI: 10.24015/ebcmed.japm.2017.0027
Aim of review
We reviewed the study of carbamylated erythropoietin (CEPO) and its probable mechanism involved in the regulation of tissue-protection.
Recent published literatures in this area were inclusive and reviewed.
CEPO has equivalent tissue-protective properties as recombinant human erythropoietin (rhEPO) but with non-erythropoietic effects. It shows protective properties on nervous system, heart, kidney and some other organs, which are associated with inhibition of apoptosis, restoration of vascular autoregulation and attenuation of inflammatory responses. However, the underlying mechanism of CEPO responsible for its beneficial effects is still not well-known.
CEPO gradually turned into a promising drug candidate at least for many diseases caused by ischemia reperfusion injury. The safety and efficacy of CEPO in clinical are warranted in the future.
Declaration of Interests
All authors have no conflicts of interest to declare for this work.
This is an open-access article, published by Evidence Based Communications (EBC). This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium or format for any lawful purpose. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.